Summary
Zogenix, Inc. (Zogenix) is a pharmaceutical company that develops and commercializes injectable therapies and delivery systems for treating central nervous system disorders and pain. The company’s product portfolio includes Zohydro ER, Sumavel DosePro and undisclosed dosepro CNS product candidate. Its pipeline products include Relday and ZX008. Zogenix’s Sumavel DosePro is a prefilled needle-free delivery system that treats people with acute migraine or cluster headaches. The company partners with Battelle to offer DosePro technology to its pharmaceutical partners. It also provides education materials on therapeutic products for patients and physicians. Zogenix is headquartered in Emeryville, California, the US.
Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Zogenix, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Zogenix, Inc., Medical Devices Deals, 2010 to YTD 2016 10
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Zogenix, Inc., Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Zogenix Secures US$15 Million In Venture Financing 13
Partnerships 15
Mallinckrodt Pharma And Zogenix Terminates Co-Promotion Agreement For Sumavel DosePro 15
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 16
Zogenix Enters Into Co-Promotion Agreement With Valeant Pharma For Migranal Nasal Spray 17
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 19
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 20
Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro 21
Zogenix Terminates Co-Promotion Agreement With Astellas Pharma US For Sumavel DosePro 23
Licensing Agreements 24
Zogenix Amends Licensing Agreement with Daravita 24
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 25
Zogenix Amends Agreement with Elan Pharma 26
Zogenix Enters Into Licensing Agreement With DURECT 27
Equity Offering 29
Zogenix Raises USD98.3 Million in Public Offering of Shares 29
Zogenix Completes Public Offering Of Shares For US$69 Million 31
Zogenix Announces Public Offering Of Shares For Up To US$25 Million 33
Zogenix Completes Public Offering Of Units For US$70 Million 34
Zogenix Completes Public Offering Of Common Stock For US$61.4 Million 36
Zogenix Completes Private Placement Of Common Stock For US$1.5 Million 38
Zogenix Completes IPO For US$57.7 Million 39
Asset Transactions 41
Pernix Acquires Zohydro ER Business from Zogenix 41
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 43
Cowen Healthcare Royalty Partners Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix 44
Acquisition 46
Zogenix Acquires Brabant Pharma for USD130 Million 46
Zogenix, Inc. - Key Competitors 48
Key Employees 49
Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
Zogenix, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Zogenix, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Zogenix, Inc., Deals By Therapy Area, 2010 to YTD 2016 9
Zogenix, Inc., Medical Devices Deals, 2010 to YTD 2016 10
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Zogenix Secures US$15 Million In Venture Financing 13
Mallinckrodt Pharma And Zogenix Terminates Co-Promotion Agreement For Sumavel DosePro 15
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 16
Zogenix Enters Into Co-Promotion Agreement With Valeant Pharma For Migranal Nasal Spray 17
Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 19
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 20
Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro 21
Zogenix Terminates Co-Promotion Agreement With Astellas Pharma US For Sumavel DosePro 23
Zogenix Amends Licensing Agreement with Daravita 24
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 25
Zogenix Amends Agreement with Elan Pharma 26
Zogenix Enters Into Licensing Agreement With DURECT 27
Zogenix Raises USD98.3 Million in Public Offering of Shares 29
Zogenix Completes Public Offering Of Shares For US$69 Million 31
Zogenix Announces Public Offering Of Shares For Up To US$25 Million 33
Zogenix Completes Public Offering Of Units For US$70 Million 34
Zogenix Completes Public Offering Of Common Stock For US$61.4 Million 36
Zogenix Completes Private Placement Of Common Stock For US$1.5 Million 38
Zogenix Completes IPO For US$57.7 Million 39
Pernix Acquires Zohydro ER Business from Zogenix 41
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 43
Cowen Healthcare Royalty Partners Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix 44
Zogenix Acquires Brabant Pharma for USD130 Million 46
Zogenix, Inc., Key Competitors 48
Zogenix, Inc., Key Employees 49
Zogenix, Inc., Other Locations 50
Zogenix, Inc., Subsidiaries 50
List of Figures
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Zogenix, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Zogenix, Inc., Medical Devices Deals, 2010 to YTD 2016 10
